Treating multiple sclerosis (MS) with monoclonal antibodies ... Following this, the newer anti-CD20 mAbs ocrelizumab and ofatumumab, which are currently being tested in Phase II for MS, are ...

Ocrelizumab showed higher adherence and ... in pivotal clinical trials among patients with different types of multiple sclerosis (MS). The analysis of 30 studies on real-world use of the ...

Anti-CD20 agents: B lymphocyte depletion: Rituximab no longer being pursued for multiple sclerosis (MS) indication. Ocrelizumab Phase II with positive results, several Phase III underway.

The treatment of multiple sclerosis (MS) has improved dramatically ... who previously worked to develop Ocrevus (ocrelizumab) for both relapsing-remitting and primary-progressive MS while at ...

According to the MS Society, certain medications like ocrelizumab (Ocrevus) can slow the progression of the disease in primary progressive multiple sclerosis, and syponimod (Mayzent) can help with ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

🔊 Listen to Post Ocrevus Treatment For Multiple Sclerosis. Ocrevus, also known by its generic name ocrelizumab, is an immunotherapy drug commonly used to treat two types of multiple sclerosis ...